+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Collagen Inhibitors - Pipeline Insight, 2021

  • ID: 5310612
  • Clinical Trials
  • March 2021
  • Region: Global
  • 60 Pages
  • DelveInsight

FEATURED COMPANIES

  • Matrizyme
  • miRagen Therapeutics
  • NeuMedics
  • Processa Pharmaceuticals
  • Roche
  • Shanghai Genomics
This “Collagen inhibitors - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Collagen inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Collagen inhibitors Understanding


Collagen inhibitors: Overview


Collagen is an essential part of the framework of the design of our various body tissues. It is the major insoluble fibrous protein in the extracellular matrix and in connective tissue.

Function -Collagen is a member of a family of naturally occurring proteins. It is one of the most plentiful proteins present in mammals and it is responsible for performing a variety of important biological functions. It is most well-known for the structural role it plays in the body. It is present in large quantities in connective tissue and provides tendons and ligaments with tensile strength and skin with elasticity. It often works in conjuction with other important proteins such as keratin and elastin.

Collagen inhibitors- Inhibition of collagen formation is an attractive target to reduce excessive formation of fibrotic tissue. Unlike canonical inhibitors of excessive accumulation of collagen-rich deposits, inhibition of collagen fibril formation targets a specific, extracellular event. Blocking collagen fibril formation may serve as an independent or supporting method to reduce excessive, localized accumulation of collagen-rich deposits.Antibody-based inhibitors of collagen fibril formation are promising therapeutic agents with a potential to limit localized fibrosis in a number of tissues.

Collagen inhibitors Emerging Drugs Chapters


This segment of the Collagen inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Collagen inhibitors Emerging Drugs


Remlarsen: miRagen Therapeutics

Remlarsen is a microRNA-29 replacement therapy, being developed by miRagen Therapeutics for the treatment of eye disorders. The drug is currently in preclinical stage for the treatment of eye disorders. In preclinical studies Remlarsen treatment appeared to reduce corneal hazing and scarring beginning at 10 days post-burn. Dose and treatment schedule were optimized in preparation for enabling toxicology studies to support human clinical trials.

Hydronidone: Shanghai Genomics

Hydronidone is a Collagen inhibitor being developed by Shanghai Genomics for several indications. The drug is in phase 2 of clinical trial for the treatment of Hepatic fibrosis.

Collagen inhibitors: Therapeutic Assessment


This segment of the report provides insights about the different Collagen inhibitors drugs segregated based on following parameters that define the scope of the report, such as:


Major Players working on Collagen inhibitors


There are approx. 10+ key companies which are developing the Collagen inhibitors. The companies which have their Collagen inhibitors drug candidates in the most advanced stage, i.e. phase 2 include, miRagen Therapeutics.

Phases


This report covers around 10+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage products (Phase I/II and Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Collagen inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Infusion
  • Intradermal
  • Intramuscular
  • Intranasal
  • Intravaginal
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical.
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Vaccines
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Collagen inhibitors: Pipeline Development Activities


The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Collagen inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities


The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Collagen inhibitors drugs.

Report Highlights


The companies and academics are working to assess challenges and seek opportunities that could influence Collagen inhibitors R&D. The therapies under development are focused on novel approaches for Collagen inhibitors.

Collagen inhibitors Report Insights

  • Collagen inhibitors Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Collagen inhibitors Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions Answered


Current Scenario and Emerging Therapies:

  • How many companies are developing Collagen inhibitors drugs?
  • How many Collagen inhibitors drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for Collagen inhibitors?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Collagen inhibitors therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Collagen inhibitors and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • miRagen Therapeutics
  • Shanghai Genomics
  • Matrizyme
  • Roche
  • NeuMedics
  • Processa Pharmaceuticals

Key Products

  • Remlarsen
  • Hydronidone
  • MZ-004
  • Pirfenidone
  • NM 108
  • Halofuginone
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Matrizyme
  • miRagen Therapeutics
  • NeuMedics
  • Processa Pharmaceuticals
  • Roche
  • Shanghai Genomics

IntroductionExecutive Summary
Collagen inhibitors: Overview
  • Structure
  • Mechanism of Action

Pipeline Therapeutics
  • Comparative Analysis

Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Collagen inhibitors - Analytical Perspective
In-depth Commercial Assessment
  • Collagen inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends

Collagen inhibitors Collaboration Deals
  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Pre-registration)
  • Comparative Analysis

Drug name: Company name
  • Product Description
  • Research and Development
  • Product Development Activities

Mid Stage Products (Phase II)
  • Comparative Analysis

Remlarsen : miRagen Therapeutics
  • Product Description
  • Research and Development

Comparative Analysis
Hydronidone : Shanghai Genomics
  • Product Description

Research and Development
  • Product Development Activities
  • Research and Development
  • Product Development Activities

Pre-clinical and Discovery Stage Products
  • Comparative Analysis

Drug name: Company name
  • Product Description
  • Research and Development
  • Product Development Activities

Inactive Products
  • Comparative Analysis

Collagen inhibitors Key CompaniesCollagen inhibitors Key ProductsCollagen inhibitors- Unmet NeedsCollagen inhibitors- Market Drivers and BarriersCollagen inhibitors- Future Perspectives and ConclusionCollagen inhibitors Analyst ViewsCollagen inhibitors Key CompaniesAppendix
List of Tables
Table 1 Total Products for Collagen inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
List of Figures
Figure 1 Total Products for Collagen inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • miRagen Therapeutics
  • Shanghai Genomics
  • Matrizyme
  • Roche
  • NeuMedics
  • Processa Pharmaceuticals
Note: Product cover images may vary from those shown